Published on
The Food and Drug Administration (FDA) has authorized a new robotic device that can autonomously draw blood from a patient’s arm without hands-on operator intervention. Designed for adult outpatient blood collection, the robot essentially performs the entire venipuncture. First it uses near-infrared imaging and Doppler ultrasound to identify an appropriate vein, then applies the tourniquet, disinfects the skin, inserts the needle, changes collection tubes, disposes the needle, and applies a bandage. A trial involving 1,633 patients at 2 teaching hospitals in the Netherlands published in Clinical Chemistry this month shows the device achieved a 94.5% first-stick success rate. No serious adverse events occurred, and 46.8% of patients strongly preferred or preferred the robot, with another 34.9% have no preference between the robot and manual phlebotomy. The FDA announcement specifies the safety stops, such as how excessive movement on the part of the patient will cause the needle to detach automatically and end the procedure. Likewise, if the robot cannot identify a suitable vein, it will not continue to the venipuncture.
Your business case: Marketed as Aletta by the Dutch company Vitestro, the robot was approved for use in Europe 2 years ago. The idea is that 1 human phlebotomist can oversee up to 3 robotic devices at the same time, ideally increasing clinical capacity for healthcare organizations and providing faster access to blood draws for patients. For urgent cares, real-world questions remain about cost, staffing, throughput, space requirements, patient acceptance, maintenance, and integration into workflows.